Table 3.
Drug search results for sarcoma
| Name | Approved | ATC L | CanceRx | Score | Degree |
|---|---|---|---|---|---|
| Imatinib | yes | yes | yes | 1 | 413 |
| Staurosporine | no | no | no | 0.995 | 393 |
| Sorafenib | yes | yes | yes | 0.991 | 401 |
| Lapatinib | yes | yes | yes | 0.984 | 387 |
| Sunitinib | yes | yes | yes | 0.983 | 388 |
| Alvocidib | no | no | no | 0.98 | 381 |
| Dasatinib | yes | yes | yes | 0.978 | 381 |
| Nilotinib | yes | yes | yes | 0.978 | 386 |
| AT-7519 | no | no | no | 0.977 | 377 |
| SNS-032 | no | no | no | 0.976 | 376 |
| Erlotinib | yes | yes | yes | 0.976 | 381 |
| Pazopanib | yes | yes | yes | 0.975 | 375 |
| Crizotinib | yes | yes | yes | 0.974 | 377 |
| Midostaurin | yes | yes | yes | 0.974 | 377 |
| Enzastaurin | no | no | no | 0.974 | 376 |
Listed are the top 15 drug results reported by CADDIE for sarcoma. Each row contains the drug name, approval by FDA, EMA or HC, whether it is listed as antineoplastic or immunomodulating agent (ATC class L) by the WHO, whether it is contained in CanceRx, the normalized score and the node degree in the drug–gene-interactome (BioGRID).